Asset Details
Do you wish to reserve the book?
Integrating multi‐omics features enables non‐invasive early diagnosis and treatment response prediction of diffuse large B‐cell lymphoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Integrating multi‐omics features enables non‐invasive early diagnosis and treatment response prediction of diffuse large B‐cell lymphoma
Do you wish to request the book?
Integrating multi‐omics features enables non‐invasive early diagnosis and treatment response prediction of diffuse large B‐cell lymphoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Integrating multi‐omics features enables non‐invasive early diagnosis and treatment response prediction of diffuse large B‐cell lymphoma
2025
Overview
Background Multi‐omics features of cell‐free DNA (cfDNA) can effectively improve the performance of non‐invasive early diagnosis and prognosis of cancer. However, multimodal characterization of cfDNA remains technically challenging. Methods We developed a comprehensive multi‐omics solution (COMOS) to specifically obtain an extensive fragmentomics landscape, presented by breakpoint characteristics of nucleosomes, CpG islands, DNase clusters and enhancers, besides typical methylation, copy number alteration of cfDNA. The COMOS was tested on 214 plasma samples of diffuse large B‐cell lymphoma (DLBCL) and matched healthy controls. Results For early diagnosis, COMOS improved the area under the curve (AUC) value to .993 compared with the individual omics model, with a sensitivity of 95% at 98% specificity. Detection sensitivity achieved 91% at 99% specificity in early‐stage patients, while the AUC values of the individual omics model were 0.942, 0.968, 0.989, 0.935, 0.921, 0.781 and 0.917, respectively, with lower sensitivity and specificity. In the treatment response cohort, COMOS yielded a superior sensitivity of 88% at 86% specificity (AUC, 0.903). COMOS has achieved excellent performance in early diagnosis and treatment response prediction. Conclusions Our study provides an effectively improved approach with high accuracy for the diagnosis and prognosis of DLBCL, showing great potential for future clinical application. Key points A comprehensive multi‐omics solution to specifically obtain an extensive fragmentomics landscape, presented by breakpoint characteristics of nucleosomes, CpG islands, DNase clusters and enhancers, besides typical methylation, copy number alteration of cfDNA. Integrated model of cfDNA multi‐omics could be used for non‐invasive early diagnosis of DLBCL. Integrated model of cfDNA multi‐omics could effectively evaluate the efficacy of R‐CHOP before DLBCL treatment. A comprehensive multi‐omics solution capable of obtaining fragmentomics landscape of cfDNA was developed and followed by an integrated model for non‐invasive early diagnosis of DLBCL, achieving excellent efficacy of R‐CHOP before DLBCL treatment.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
/ Aged
/ Biomarkers, Tumor - genetics
/ Cell-Free Nucleic Acids - analysis
/ Cell-Free Nucleic Acids - blood
/ cfDNA
/ Cyclophosphamide - therapeutic use
/ DLBCL
/ Doxorubicin - therapeutic use
/ Early Detection of Cancer - methods
/ Female
/ Humans
/ Lymphoma
/ Lymphoma, Large B-Cell, Diffuse - blood
/ Lymphoma, Large B-Cell, Diffuse - diagnosis
/ Lymphoma, Large B-Cell, Diffuse - drug therapy
/ Lymphoma, Large B-Cell, Diffuse - genetics
/ Male
